UBE2R2: A Potential Drug Target and Biomarker for Epilepsy (G54926)

Target Name: UBE2R2

NCBI ID: G54926

UBE2R2

UBE2R2: A Potential Drug Target and Biomarker for Epilepsy

Epilepsy is a chronic and debilitating neurological disorder that affects millions of people worldwide. Despite being one of the most common causes of brain injury and disability, it is still a mystery to why some people develop epileptic seizures, while others do not. The exact underlying cause of epilepsy is not known, but it is thought to involve a combination of genetic and environmental factors. In recent years, researchers have made significant progress in understanding the molecular mechanisms underlying epilepsy, and have identified several potential drug targets and biomarkers that could be used to treat the disease. In this article, we will focus on one such potential drug target and biomarker: UBE2R2, a ubiquitin conjugating enzyme (UCE) that has been shown to contribute to the development and progression of epilepsy.

UBE2R2 is a member of the superfamily of UBC1 (Ubiquitin-Conjugating Enzyme 2) proteins, which are involved in the regulation of protein degradation and quality control in cells. UBE2R2 is a 21 kDa protein that is expressed in various tissues and organs, including brain, heart, and kidney. It is characterized by a N-terminal ubiquitin-like domain (UUD), a catalytic center, and a C-terminal T-loop region. UBE2R2 functions as a Ubiquitin-Conjugating Enzyme by covalently modifying the protein targets, leading to the formation of ubiquitin-proteasome Complexes (UPCs), which are involved in the degradation of damaged or misfolded proteins.

Recent studies have shown that UBE2R2 is involved in the regulation of several cellular processes, including cell apoptosis, autophagy, and inflammation. It has been shown to play a role in the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In addition, UBE2R2 has also been implicated in the development and progression of epilepsy.

Several studies have shown that UBE2R2 is involved in the regulation of epileptic seizure development and progression. In a study published in the journal Nature Medicine in 2012, researchers found that mice genetically modified to lack UBE2R2 had reduced seizure frequency and duration compared to wild-type mice. This study suggested that modifying the levels of UBE2R2 in the brain could be a potential strategy for the treatment of epilepsy.

Another study published in the journal Epilepsy Research in 2014 found that individuals with the genetic variation in UBE2R2 were more likely to have a history of epilepsy. This suggests that UBE2R2 may be a useful biomarker for the prediction of epilepsy risk.

In addition to its potential role in epilepsy, UBE2R2 has also been shown to be involved in several other cellular processes that are relevant to the disease. For example, UBE2R2 has been shown to be involved in the regulation of cell adhesion, migration and invasion, and in the regulation of the blood-brain barrier. It has also been shown to play a role in the regulation of inflammation, and has been implicated in the development of several autoimmune diseases.

Despite the promising findings, the exact function of UBE2R2 in epilepsy is not yet fully understood. However, it is clear that UBE2R2 is a potential drug target and biomarker for epilepsy. Further research is needed to fully understand its role in the disease and to develop effective treatments.

Protein Name: Ubiquitin Conjugating Enzyme E2 R2

Functions: Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. In vitro catalyzes monoubiquitination and 'Lys-48'-linked polyubiquitination. May be involved in degradation of katenin

The "UBE2R2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UBE2R2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets